




## SUPPLEMENTARY MATERIAL



**Supplementary figure 1.** Flow cytometry gating strategy. **(a–i)** Representative plots of SARS-CoV-2 inoculated whole blood stained with fluorophore-antibodies and a viability dye for flow cytometry. **(j–l)** For comparison, representative plots of virus-naïve whole blood stained in the same fashion are also provided for the monocyte gates. All samples had > 95% leukocyte viability.



**Supplementary figure 2.** Upregulation of **(a)** CD16 and HLA-DR on monocytes and **(b)** CD11b on neutrophils exposed to SARS-CoV-2. SARS-CoV-2 inoculated lepirudin-anticoagulated whole blood was analysed with flow cytometry at 24 (n = 6) and 3 hours post-inoculation (n = 4) respectively. Surface markers were quantified as MFI. MOI = multiplicity of infection; MFI = median fluorescence intensity; \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$  using a one-way ANOVA.



**Supplementary figure 3.** SARS-CoV-2 serology testing of plasma from whole blood used for C5a ELISA studies. Pre-COVID-19 serum (- Sera; i.e. serum negative for SARS-CoV-2) was used as a negative control and a biological standard NIBSC 20/130 (+ Sera) was used as a positive control. The data here are from samples diluted at 1:10. OD 450 = optical density at the wavelength of 450 nm.

C5a ELISA 30min		C5a ELISA 24h		C5a ELISA Pathways	
<i>Sex</i>	<i>Age (Years)</i>	<i>Sex</i>	<i>Age (Years)</i>	<i>Sex</i>	<i>Age (Years)</i>
Male	30	Male	40	Female	20
Male	23	Male	26	Female	20
Female	21	Male	36	Male	31
				Male	27
				Female	57
Flow Cytometry 3h		Flow Cytometry 24h			
<i>Sex</i>	<i>Age (Years)</i>	<i>Sex</i>	<i>Age (Years)</i>		
Male	36	Male	32		
Male	41	Male	24		
Male	25	Male	30		
Female	26	Female	19		
		Male	23		
		Female	25		

**Supplementary table 1. Research Participants for this Study.** Participants were recruited from the local Brisbane area and had no history of COVID-19, no history of acute illness or vaccination in the last 2 weeks, no immunodeficiencies or autoinflammatory/autoimmune conditions, and were not on any immunomodulatory medications (e.g. corticosteroids). No significant sex or age differences were found between the cohorts at different time points for the ELISA and flow cytometry experiments.